Lindeza

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lindeza

Lindeza is a pharmaceutical product, clinically recognized as an effective aid in weight management, that exerts its function exclusively within the digestive system. It is defined by its core ingredient and its pharmacological approach to calorie reduction.

Property Description
Active Ingredient Orlistat (INN)
Form Hard-gelatin capsule
Pharmacological Class Intestinal Lipase Inhibitor, Anti-obesity Agent
Common Use Supports long-term weight reduction and weight maintenance
Origin Semisynthetic (chemically derived from lipstatin)

Defining Lindeza and its Pharmacological Class

Lindeza is a medicine that contains the active ingredient Orlistat, which is classified within the unique pharmacological group of lipase inhibitors. This medication represents the application of Orlistat designed to work solely within the gut, making its effect primarily non-systemic. This is a key differentiating factor from other anti-obesity agents that alter appetite by influencing brain chemistry.

Orlistat is a semisynthetic compound, chemically modified from the natural substance lipstatin.

Composition and Unique Application

The medicine is supplied as a single-ingredient capsule intended for oral administration. The active component, Orlistat, is a fine crystalline powder that is practically insoluble in water, a property essential for its minimal systemic absorption.

This formulation’s unique positioning is that it is often reserved for patients who require a medically supervised program for weight management. Clinical experience has affirmed that the full therapeutic benefit of Orlistat is realized when used as part of a structured program that includes a reduced-calorie, low-fat diet.

General Therapeutic Purpose

The core therapeutic purpose of Lindeza is to support weight goals by creating a caloric deficit via inhibiting the absorption of dietary fat.

Orlistat works by forming a covalent bond with and inactivating the gastric and pancreatic lipases, the enzymes responsible for fat breakdown. Consequently, undigested fat molecules are not absorbed into the body, which directly contributes to weight loss by preventing the absorption of fatty acids. The general benefit is assisting adults in maintaining a healthier body weight following an initial weight reduction phase, demonstrating a durable, clinically recognized effect.

Regulatory References

  1. Orlistat - StatPearls - NCBI Bookshelf

What side effects are possible with Lindeza?

Possible Side Effects and Safety Information

The safety profile of Lindeza (Orlistat) is structured around adverse reactions that are primarily concentrated in the Gastrointestinal Disorders system, stemming directly from its pharmacological action as an intestinal lipase inhibitor. The incidence of these effects is classified based on official regulatory documentation.


Frequency-Classified Adverse Reactions

The most frequent adverse events are generally observed early in treatment, often within the first three months, and are classified as follows:

  • Very Common (1/10): Oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, increased defecation, abdominal pain/discomfort, and headache.
  • Common (1/100 to <1/10): Fecal incontinence, nausea, infectious diarrhea, rectal pain/discomfort, dizziness, and anxiety.

Serious Adverse Reactions and Systemic Safety

Official post-marketing surveillance reports document rare but serious adverse reactions that affect systemic organ classes. These include severe cases of Severe Liver Injury (such as hepatocellular necrosis or acute hepatic failure) and complications within the Renal and Urinary Disorders class, specifically Oxalate Nephropathy (kidney damage) associated with hyperoxaluria.

Lindeza may also impair the absorption of fat-soluble vitamins (A, D, E, and K). Additionally, rare reports exist of serious Immune System Disorders, including hypersensitivity reactions such as anaphylaxis.


Safety Constraints and Special Populations

Regulatory documentation defines specific constraints. Lindeza is contraindicated in individuals with pre-existing conditions such as chronic malabsorption syndrome and cholestasis. Caution is necessary for certain patient groups; for example, patients with underlying Chronic Kidney Disease may be at increased risk for oxalate nephropathy. Furthermore, use is generally contraindicated during pregnancy.

Overdose and Emergency Response

Lindeza Overdose and when to seek help

Official regulatory information for Lindeza (Orlistat) focuses on the required emergency actions rather than specific acute systemic symptoms, due to the drug’s minimal absorption.

Overdose Scope Official Regulatory Statement
Documented Overdose Presentations Clinical studies involving mathbf single doses up to 800 mg and repeated doses showed mathbf no significant adverse findings [FDA/EMA].
Physiological Systems Affected Any potential systemic effects resulting from overdose are described as mathbf likely to be rapidly reversible [EMA].
Dose-Related Factors Exposures studied included a mathbf single dose up to 800 mg and mathbf multiple doses up to 400 mg three times daily for 15 days.

Required Emergency Response

Emergency-response statements (as written in official documents):

  • In the event of a significant overdose, mathbf seek emergency medical attention immediately and mathbf contact a Poison Control Center right away.
  • If a significant overdose occurs, the patient should be mathbf observed for at least 24 hours.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by stating that mathbf no significant adverse findings were observed, which aligns with the drug’s non-systemic effect. Despite the minimal documented acute toxicity, regulatory authorities mathbf mandate urgent help-seeking (emergency medical attention) to ensure professional management. The required mathbf 24-hour observation period is the key procedural step for monitoring following a significant overdose.

Therapeutic Uses of Lindeza

The therapeutic utility of Lindeza (Orlistat) is centered on providing a pharmacological aid for managing chronic excess weight and the associated metabolic health risks.


Treating Clinical Obesity and Significant Overweight

Lindeza is commonly used to help with obesity management and supports long-term management and maintenance of weight loss in appropriate patients. This drug is generally applied across domains where additional symptomatic support is needed to address conditions associated with chronic weight accumulation and excess adiposity, including conditions characterized by periods of heightened symptoms associated with obesity or being overweight when other health risk factors are present. The primary therapeutic benefit is that it helps support weight reduction, which is considered relevant for easing the symptoms that create noticeable physiological strain associated with excess weight.


Supporting Long-Term Weight Stability and Metabolic Health

The medication is considered relevant for use in clinical settings where symptoms related to functional stability become affected, particularly addressing the difficulty of preventing weight regain following prior weight loss efforts. Furthermore, Lindeza may be part of symptomatic management in situations where patients experience symptoms that create noticeable physiological strain associated with the overall health consequences of excess weight.

“This therapy is often used to help patients manage and maintain their weight reduction efforts over time.”

The support provided contributes to easing the overall symptom load by assisting in the management of associated metabolic risk factors, which may help patients cope more steadily with the overall health consequences of obesity.

Quick Fact: Support for Physiological Strain Lindeza is commonly used to help with symptoms that create noticeable physiological strain and systemic imbalance associated with chronic excess weight.

Regulatory References

  1. NIH DailyMed drug label information

Eligibility and Restrictions for Use

The eligibility for using Lindeza is strictly defined by government regulatory agencies based on age, BMI, and pre-existing medical conditions.

Category Official Regulatory Status
Permitted Adults Individuals with an initial Body Mass Index (BMI) 30 kg/m^2, or 27 kg/m^2 in the presence of associated risk factors.
Permitted Adolescents Approved for use in adolescents 12 years of age for prescription-strength formulations.
Contraindicated Groups Chronic Malabsorption Syndrome, Cholestasis, or known hypersensitivity to the active ingredient.
Pregnancy and Lactation Use is contraindicated during both pregnancy and breast-feeding.

The medicine is generally not recommended for children under 12 years of age. Special regulatory caution is advised for patients with chronic kidney disease or a history of oxalate nephrolithiasis (kidney stones). Before use, other organic causes of obesity, such as hypothyroidism, must be ruled out.

What should I know about interactions with other medicines?

The interaction profile of Lindeza is structured around a pharmacokinetic effect defined by the reduced gastrointestinal absorption of specific lipophilic co-administered agents. This mechanism necessitates adherence to regulatory constraints detailed in official prescribing information.

Interaction-Related Restrictions

Specific restrictions apply to certain combinations. Co-administration of Lindeza and Acarbose is generally advised to be avoided. Simultaneous administration with Cyclosporine is officially restricted, as it leads to a documented reduction in the medicine's plasma levels.

Officially Documented Exposure Alterations

Several other agents and substance classes demonstrate reduced systemic exposure. These include Amiodarone, Levothyroxine, and Warfarin (due to reduced Vitamin K absorption), as well as Antiretroviral HIV Medications and Fat-Soluble Vitamins (A, D, E, K). To manage these exposure alterations, the regulatory label imposes mandatory timing requirements: Levothyroxine must be administered at least four hours apart, and Cyclosporine three hours after Lindeza.

Other Specific Interaction Constraints

A significant drug-food interaction is documented, where consuming a diet high in fat (over 30% of total daily calories) increases the incidence of gastrointestinal adverse events. Additionally, a population-specific caution notes an increased risk of hyperoxaluria and oxalate nephropathy in individuals with underlying chronic kidney disease.

Mechanism of Action

Targeted Inactivation of Digestive Lipases

The drug exerts its primary mechanistic action by forming a covalent bond with the active site of both gastric and pancreatic lipases. These enzymes are the core biological targets essential for breaking down dietary triglycerides. This binding irreversibly inactivates the lipases, suppressing the molecular step required for fat absorption.

Localized Blockade of Fat Hydrolysis

Lindeza's effect is entirely non-systemic, localized to the gut lumen, creating an intestinal pathway blockade. Since the key lipases are rendered inactive, dietary triglycerides cannot be hydrolyzed into absorbable free fatty acids and monoglycerides. The resulting physiological consequence is the excretion of undigested fat, which bypasses systemic circulation.

Mechanism-Driven Caloric Deficit

The functional outcome of this enzyme inhibition is a reduction in the amount of energy (calories) assimilated by the body from ingested fat. This mechanism is selectively constrained; it is dependent on the presence of dietary fat and does not interfere with the absorption of calories from carbohydrates or proteins. The creation of this deficit is the direct physiological consequence of the mechanism.

Dosage and Administration Information

How to Use Lindeza (Orlistat): Official Administration Guidelines

Lindeza, containing the active ingredient Orlistat, is a medicine with a highly specific, conditional administration protocol. It is used as an adjunct to a nutritionally balanced, reduced-calorie, low-fat diet. The administration schedule is tied directly to the ingestion of dietary fat.


Administration Scope

Feature Instruction
Route of administration Oral
Dosing schedule 120 mg hard-gelatin capsule three times a day (TID). The maximum recommended dose is 120 mg TID.
Timing in relation to meals The dose must be taken immediately before, during, or up to one hour after each main meal that contains fat.
Missed-dose rule If a main meal is missed or contains no fat, the dose must be omitted.

Procedural Administration Rules

Official step sequence:

  • Take one 120 mg capsule with a main meal that contains fat.
  • The capsule must be administered immediately before, during, or within one hour after that meal.
  • If a meal is missed or does not contain fat, the specific dose associated with that meal must be omitted.

Special procedural conditions:

  • Timing with supplements: The administration of a multivitamin supplement containing fat-soluble vitamins (A, D, E, K) must be separated by at least 2 hours from the Orlistat dose.
  • Course duration: Therapy should be discontinued if the patient has not lost at least 5% of body weight within the initial 12 weeks of treatment.

The official protocol defines a conditional, three-times-daily oral regimen that is functionally linked to dietary intake, requiring both precise timing relative to the meal and a determination of the meal's fat content. This usage structure must be followed to maintain consistency with the standardized approach.

Recent Clinical Evidence

Lindeza (orlistat) is an FDA-approved lipase inhibitor indicated for obesity management and to reduce the risk of weight regain following initial weight loss. Its use is recommended in conjunction with a reduced-calorie, balanced diet.

Efficacy in Weight Management

Clinical trials of up to two years demonstrated that adults taking orlistat, combined with diet and lifestyle changes, achieved greater weight reduction compared to those who only implemented lifestyle changes. Pooled data from multiple studies suggest that individuals taking orlistat typically lose 2–3 kilograms (about 4–7 pounds) more than those receiving placebo over one year.

Outcome Measure Finding (vs. Placebo)
Weight Loss Greater percentage of patients achieved ge 5% body weight decrease.
Weight Regain Reduced risk of regaining lost weight over a four-year period.

Metabolic and Cardiovascular Outcomes

Evidence suggests that the weight loss facilitated by orlistat may lead to modest improvements in metabolic risk factors. In studies of obese patients with or without Type 2 diabetes, treatment was associated with a modest decrease in both systolic and diastolic blood pressure, as well as an improved lipid profile (cholesterol levels). Furthermore, clinical data indicated that the use of orlistat was associated with a reduced incidence of developing Type 2 diabetes in obese individuals compared to lifestyle changes alone.

Safety Profile

The majority of research reports that the drug is generally well tolerated, with the most commonly reported effects being gastrointestinal in nature. Safety studies and an integrated analysis of clinical trial data have investigated the potential for liver-related issues, concluding that while rare idiosyncratic liver injury cannot be completely excluded, there was no significant signal for hepatic damage in the extensive clinical development program.

Key Studies & References

  1. Efficacy of Orlistat in type 2 diabetes – a systematic review and meta analysis
  2. Obesity: identification, assessment and management - NICE Clinical Guideline CG189

Frequently Asked Questions (FAQ)

Common questions about Lindeza (FAQ)


Q: How quickly can someone expect to see any effects from Lindeza?

A: Effects related to the medication's mechanism, such as changes in stool consistency or frequency, generally begin within 1 to 2 days after starting treatment. Clinical studies often use a 12-week timeline for assessing the efficacy of the treatment, as official guidelines often mention stopping treatment if at least 5% of the initial body weight has not been lost within this period.


Q: How long is a typical course of treatment with Lindeza?

A: Regulatory guidance dictates that the treatment's success is generally reviewed if a 5% body weight loss threshold is not met within the initial 12 weeks. While there is no definitive maximum duration specified in regulatory documents for successful responders, therapy is typically subject to regular review by the prescribing healthcare professional.


Q: What should I do if a side effect of Lindeza seems persistent or concerning?

A: Patient information indicates that individuals who experience concerning symptoms, such as signs of a serious liver issue (like pale stools or dark urine) or a severe allergic reaction, should seek attention from a healthcare provider or pharmacist.


Q: Does Lindeza have any known interactions with common over-the-counter pain relievers?

A: Regulatory documents primarily focus on specific drug classes with documented absorption issues. While most common over-the-counter pain relievers are generally not listed as having a major contraindication, for any combination of medications or supplements, consulting a healthcare professional is consistent with regulatory guidance.


Q: Will taking Lindeza make me drowsy or affect my ability to drive?

A: The official product information lists dizziness as a common side effect. Although the medicine is not systemically absorbed, patients are generally advised to note how the medicine affects them, particularly if they experience dizziness, before engaging in activities like driving or operating machinery.


Q: Can I stop taking Lindeza suddenly, or does the dose need to be adjusted down?

A: Regulatory summaries indicate that when the active ingredient is discontinued, the body's natural fat absorption process returns to normal within 48 to 72 hours. Unlike some other medications, official labels do not specify a mandatory tapering schedule or warn against the abrupt discontinuation of Lindeza.


Q: Is Lindeza a type of weight loss drug, or does it treat a specific condition?

A: Lindeza is classified as an anti-obesity agent, specifically a lipase inhibitor. Its official indication is for the management of obesity, which is defined by specific BMI criteria and requires use in conjunction with a reduced-calorie and low-fat diet.


Q: Is a generic version of Lindeza available?

A: Yes, the active ingredient in Lindeza, Orlistat, is available in generic versions, in addition to brand-name prescription formulations.


Q: Is it safe to consume alcohol while taking Lindeza?

A: Official drug labels generally do not list a direct major interaction with alcohol. Questions regarding alcohol consumption are generally recommended to be raised with a healthcare provider, as it can affect overall health and adherence to the dietary requirements of the treatment program.


Q: Does Lindeza interact with any herbal supplements, like St. John's Wort?

A: Orlistat may alter the absorption of some fat-soluble compounds, and herbal supplements can often affect the way the body processes medicine. Disclosing the use of all supplements and herbal products to a healthcare provider before starting Lindeza is consistent with official guidance.


Q: Is it true that Lindeza can affect my thyroid medication?

A: Yes, official regulatory documents note that the medicine may interfere with the absorption of levothyroxine, a thyroid hormone medication. Regulatory labels state that the two medicines should be administered at least 4 hours apart. Close monitoring of thyroid function may be a part of the treatment regimen.


Q: Can I use Lindeza if I'm taking a medication for an organ transplant?

A: The official labels contain restrictions regarding the co-administration of certain transplant medications, such as Cyclosporine. Specific spacing rules (e.g., taking them 3 hours apart) are required to manage the documented reduction in the transplant medication's systemic exposure.


Q: Why is Lindeza sometimes prescribed instead of other treatments?

A: Lindeza has a unique, localized mechanism of action; it works only in the gut to block fat absorption and is not systemically absorbed into the body. This approach may make it an appropriate option for patients who cannot use or tolerate other anti-obesity agents that act on the brain or central nervous system.


Q: Does Lindeza require regular blood tests or monitoring?

A: Regulatory information advises that a patient’s progress is subject to check at regular visits. Blood and urine tests may be part of the monitoring required by a healthcare professional to check for potential issues, such as vitamin deficiencies or effects on kidney function.


Q: Are there any known allergic reactions to Lindeza I should be aware of?

A: Rare but serious hypersensitivity reactions have been reported, including anaphylaxis (a severe allergic reaction), angioedema (swelling), rash, and itching. If signs of a serious allergic reaction are noted, immediate medical attention should be sought.


Q: What precautions are listed for individuals with a history of an eating disorder?

A: Official regulatory guidance advises that caution should be exercised when considering the use of Lindeza in individuals with a history of certain underlying medical problems, including eating disorders such as anorexia nervosa or bulimia.


Q: Can I take Lindeza at the same time as my daily multivitamin?

A: No. Official guidelines state that the administration of a multivitamin supplement, especially one containing fat-soluble vitamins (A, D, E, K), is intended to be separated by at least 2 hours from the dose of Lindeza. This separation helps ensure proper vitamin absorption.


Q: What is the official warning regarding the use of Lindeza and kidney stones?

A: Official warnings note an increased risk of a condition called Oxalate Nephropathy (a form of kidney damage), which is a potential complication of fat malabsorption. This risk is specifically highlighted for individuals with Chronic Kidney Disease or a history of calcium oxalate kidney stones.


Q: Does Lindeza have any effect on blood pressure?

A: Evidence from clinical studies suggests that the weight loss achieved with the assistance of Lindeza is associated with modest improvements in metabolic risk factors. This includes a documented modest decrease in both systolic and diastolic blood pressure.


Q: Is there a link between Lindeza and increased anxiety or changes in mood?

A: Official adverse event reporting lists anxiety as a common side effect associated with the medication. The regulatory documents confirm this finding, but they typically do not link the drug to broader, nonspecific 'changes in mood' or other psychiatric disorders beyond the documented common effects.


Q: Can I use Lindeza if I have an underlying condition like chronic malabsorption syndrome?

A: No. Chronic Malabsorption Syndrome is explicitly listed as a contraindication in official regulatory documents. This means the medicine must not be used by individuals with this condition due to the high risk of worsening the existing malabsorption.

How should Lindeza be stored and disposed of?

The official labeling for Lindeza (Orlistat) mandates specific conditions for maintaining its integrity and safe disposal.

Storage Conditions

The capsules must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). The product must be protected from excessive light and humidity and kept in its tightly closed, light-resistant container. Do not use the medicine past the expiration date on the packaging.

Safety and Disposal

Lindeza must be kept out of the sight and reach of children.

Unused or expired product should be safely thrown away by following the local regulations for discarding medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lindeza found in:

A-Z Index: